The dosage wouldnt likely be too low, otherwise the dsmb would have recommended increasing.
Xanamem would likely be effective, otherwise the dsmb would have recommended some form of change.
We have established efficacy can not be stated.
Thymus stated in another thread that the Eli Lilly interim analysis showed safety but not efficacy so the whole trial was scrapped. This is a good indicator we are on track.
To suggest it is ineffective or the dosage is too low is weak speculation based on no evidence.
Since the interim analysis our market cap has moved from ~30 million to ~47 million. A 36% increase. Thats a big boost for a treatment that has never been tried before and has very little human data.
ACW Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
